



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : P. Laltlanzova, (Asst Drugs Inspector)
Lawngtlai District- 796891, Mizoram :
- Serial No. and date of Inspector's memorandum : 003/LTI-FDA/I-26 , 20-JAN-2026
- Number of Sample : NIL
- Date of receipt : 10-FEB-2026
- Names of drugs purporting to be contained in the sample : CETIRIZINE TABLETS I.P 10 MG. (SETIMED)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2026-GUW/LS/2026-27/0141	27/104	425-366	Feb-2025 Jul-2027	NA	ZEE LABORATORIES LTD., Behind 47, Industrial Area, Paonta Sahib-173025

- Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector
[the packet or on portion of sample or container]

- Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing : From 01-Apr-2026 To 15-May-2026

COMPOSITION : Each uncoated tablet is purported to contains: Cetirizine Hydrochloride IP 10 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	White, elongated, bi-convex, scored on one surface, uncoated tablets, in blister pack.	NA
2	Identification	Gives positive test for Cetirizine Hydrochloride.	NA
3	Average weight	0.13808 g	NA
4	Test for Dissolution	Complies.	NLT 75 % of claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Cetirizine Hydrochloride	10.71 mg/Tablet	10 mg/Tablet	107.1	90 % to 110 %	I.P. 2022

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Rinku Kalita

Date: 26-MAY-2026

GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

-----END OF REPORT-----

